Anteris Technologies Advances DurAVR Global Pivotal Trial with $90M Medtronic Investment and Plans $200M IPO

Jan 21, 2026 22:11 CST Updated 22:11

Anteris

Cardiac Valve Researcher

Medtronic

Chronic Disease Medical Device and Therapy Developer

Anteris TechnologiesAnnouncing its receipt of up to 90 million US dollars investment from Medtronic, which will be obtained by MedtronicAnteris Technologies 16.0% to 19.99% of the equity. Additionally,Anteris TechnologiesPlanning a $200 million underwritten public offering, with underwriters having a 30-day option to purchase an additional $30 million of common stock at the public offering price (扣除承销折扣与佣金).

The funds from this round of financing will be mainly used forSupport the next phase of growth and advance the execution of the company's clinical strategy.This includes advancing treatments for patients with severe aortic stenosis.All-in-One Bionic TAVR---DurAVRContinuous patient recruitment and trial execution for the global pivotal trial (PARADIGM trial), as well as expanded production capacity.

This investment by Medtronic,DistanceAnteris TechnologiesPublishYoga-inspired Bionic TAVR---DurAVRPositive clinical results at one year, just three months prior.

Specific Clinical Data (100 Patients at 30 Days Post-Operation)

DurAVR provides excellent hemodynamic performance with an effective orifice area (EOA) of 2.2 ± 0.3 cm²., with a mean pressure gradient (MPG) of 8.2 ± 3.1 mmHg.
At 30 days, clinical safety outcomes were favorable with no valve-related mortality and no moderate or severe paravalvular leak (PVL).
Compared with the current 11.2% to 35.3% mismatch rate of commercially available devices, the prosthetic-to-patient mismatch rate is only 3.0%., which highlights a significant reduction in key predictors of valve failure and disease progression.
In the recent consecutive 50 patient implantation surgeries, the technical success rateReached 100%.

In the overseas TAVR field competition, it is mainly a duet between Medtronic and Edwards. Previously, Medtronic, with a series of clinical studies favorable to its Evolut series of TAVR products, put Edwards in a temporary passive position. Later, Edwards went into a buying spree, once acquiring the world's two best regurgitation TAVR products (but eventually missed out due to antitrust issues).JenaValve Technology), but still holds the initiative in the TAVR field.

Medtronic previously relied solely onThe Evolut series of products, relatively speaking, are not very proactive. However, as internal adjustments come to an end, Medtronic appears to be becoming more active, especially in the cardiovascular field. Medtronic has announced that it will enter "M&A" mode, and the cardiovascular field is Medtronic's most relied-upon area; therefore, investing in and acquiring high-quality targets in the cardiovascular field has become the top choice.

Anteris TechnologiesIntegrated Bionic TAVR Subconsciously Enhances Medtronic's TAVR Future Efficacy, Boosting Medtronic's Competitiveness. Early Lock-in Will Help Medtronic Take the Initiative in Competing with Edwards, and Medtronic Also Has the Opportunity to Acquire.JenaValve Technology is competing with Edwards in both regurgitation and stenosis fields, striving to become the top player in TAVR.

DurAVR

DurAVRIt is an all-in-one, bionic-designed TAVR product with a shape similar to that of a natural valve, aiming to simulate the performance of a healthy aortic valve.

DurAVR Core Technology (ADAPT)

ADAPT is a patented bovine-derived tissue, clinically proven to be calcium-free for up to 10 years, and has been used in more than 55,000 patients worldwide (as a cardiac and vascular patch). ADAPTTissue is malleable and can be shaped for use in the DurAVR heart valve.

ADAPT Technical Advantages
Anti-calcification
The content of free aldehyde is extremely low, undetectable, which is one of the main driving factors of calcification-mediated valve degeneration.
Anti-fibrosis
The ADAPT process aims to remove heterologous pro-inflammatory factors that may cause fibrosis (e.g., residual DNA/RNA, phospholipids, α-galactose epitopes).
Reduce Leaflet Stress
Materials with high malleability and excellent flexibility can achieve long-term valve closure, thereby minimizing leaflet flutter and tremor, and further reducing the risk of valve degeneration.
Other Advantages of DurAVR
Coronary Artery Access
Large fenestrations and short stent height design to allow access to the coronary ostium for future coronary interventions.
Balloon-Expandable Stent
The cobalt-chromium alloy stent expands as the balloon inflates and is designed to control the deployment and placement of the valve.

Anteris Technologies
Anteris TechnologiesAnteris is a structural heart company dedicated to developing innovative and lasting health solutions through better science and design. Committed to helping healthcare professionals create life-changing outcomes for patients.